ArticleFrontiers in pharmacology2025
Drug-associated serotonin syndrome in elderly patients: a comprehensive disproportionality analysis based on the FAERS database.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to identify drugs associated with serotonin syndrome in elderly patients by utilizing the FDA Adverse Event Reporting System (FAERS), to provide evidence-based references for safe clinical medication practices. Methods: This study analyzed data extracted from the FAERS covering the period from Q1 2004 to Q1 2025, with the objective of identifying drugs associated with serotonin syndrome in elderly patients. Disproportionality analysis was utilized to detect potential drug-associated signals, and sensitivity analyses were performed to evaluate the stability and strength of serotonin syndrome signals associated with these drugs. Time-to-onset (TTO) analysis was conducted to investigate factors influencing the clinical presentation of serotonin syndrome. Results: Disproportionality analysis identified 68 drugs associated with serotonin syndrome in elderly patients. Among the drugs with positive signals, the most frequently reported category associated with serotonin syndrome in elderly patients was nervous system drugs, followed by antiinfectives for systemic use, alimentary tract and metabolism drugs, musculo-skeletal system drugs, dermatologicals, and respiratory system drugs. Sensitivity analyses confirmed that most positive signals remained robust. TTO analysis revealed that drug-associated serotonin syndrome onset occurred earlier in elderly female patients. Conclusion: Drug-associated serotonin syndrome risk is elevated among elderly patients. Prompt identification and discontinuation of the causative drugs are crucial for the effective management of serotonin syndrome. In clinical practice, the risk of drug-associated serotonin syndrome should be taken into account to optimize pharmacotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.